CASODEX TABLET 150mg

Product Information

Registration Status: Active

CASODEX TABLET 150mg is approved to be sold in Singapore with effective from 2000-08-07. It is marketed by ASTRAZENECA SINGAPORE PTE LTD, with the registration number of SIN11344P.

This product contains Bicalutamide 150mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.

This product is manufactured by Corden Pharma GmbH in GERMANY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Bicalutamide

Description

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is a racemic mixture consisting of equal proportions of enantiomers (R)-bicalutamide and (S)-bicalutamide. Bicalutamide binds to the androgen receptor.

Indication

For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.

Mechanism of Action

Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

Pharmacokinetics

Absorption
Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.
Distribution
Metabolism
Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.
Elimination

Clearance

* Apparent oral cl=0.32 L/h [Normal Males]

Active Ingredient/Synonyms

Bicalutamida | Bicalutamide | Bicalutamidum | Bicalutamide |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank